S&P/ASX All Ordinaries Index (ASX: XAO) shares rose by 7.55% last year and delivered total gross returns, including dividends, of 11.44%. The index closed the year at 8,420.5 points.
In comparison, the benchmark S&P/ASX 200 Index (ASX: XJO) lifted 7.49%, with total gross returns also coming in at 11.44%. The ASX 200 finished the year at 8,159.1 points.
Multiple ASX All Ords stocks delivered exceptional price growth in 2024. We provide a sample of these multi-bagger stocks below.
Here are 16 ASX shares that shot the lights out with a minimum doubling in stock price over the year.
ASX biotech share Mesoblast skyrocketed by 900% to close at $3.10 apiece on 31 December.
This ASX financial stock ripped in 2024 with the Zip share price soaring 352.5% to close at $2.96.
ASX tech share Appen catapulted 319.1% higher to close at $2.64 on 31 December.
This materials share soared 295.68% to finish the year at $5.50 per share.
The Nuix share price rocketed 232.63% higher in 2024 to close at $6.32 per share on 31 December.
Shares in ASX telecommunications company SuperLoop streaked 226.87% higher to $2.19.
Stock in social tracking app developer Life360 rose by 198.15% to finish the year at $22.54 per share.
The Spartan Resources share price rose by 171.15% in 2024. The ASX gold mining share closed the year at $1.41 apiece.
Fellow gold mining stock Ora Banda lifted 170.83% to close the year at 65 cents per share.
Shares in sports technology solutions provider Catapult lifted 169% to $3.71 over the 12 months.
ASX healthcare share Sigma leapt 162% higher to close at $2.62 on 31 December.
The Pro Medicus share price rose by 161% to finish 2024 at $250.12 per share.
The Telix Pharmaceuticals share price shot 144.14% higher to close at $24.61 on 31 December.
The Pinnacle Investment share price rose 126.69% to finish at $22.85 on 31 December.
This ASX biopharmaceutical share rocketed 120.6% to close out the year at $4.17.
TechnologyOne shares ascended 103.71% to close 2024 at $31.31 per share.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。